. 2019 Mar 28;62(1):1–7. doi: 10.33160/yam.2019.03.001

Table 2.

Selective studies of bendamustine-based therapy for untreated MCL

Phase	Treatment	n	Median age, years (range)	OR, % (CR)	Survival	TRM	Reference
III randomized	R-Bendamustine vs R-CHOP	46 vs 48	70 (65–74)	93 (40)* vs 91 (30)*	median PFS: 35.4 months vs 22.1 months	0.4%* vs 2.0%*	Rummel et al. 2013²⁷
III randomized	R-Bendamustine vs R-CHOP/R-CVP	34 vs 33	60 (28–84)* vs 58 (25–86)*	94 (50) vs 85 (27)	NA	0.5%* vs 0.5%*	Flinn et al. 2014²⁸
II two-center	R-Bendamustine + HDA + ASCT	23	57 (42–69)	96 (96)	1-year PFS: 96%, OS: 96%	0%	Armand et al. 2016³⁰
II randomized, closed prematurely	R-HCVAD/MA + ASCT vs R-Bendamustine + ASCT	17 vs 35	59 (44–66) vs 57 (33–64)	94 (35) vs 83 (40)	2-year PFS: 82% vs. 81%, OS: 88% vs. 87%	NA	Chen et al. 2017²⁹
II multicenter	R-Bendamustine + low-dose cytarabine (RBAC500)	57	71 (61–79)	91 (91)	2-year PFS: 81%, OS: 86%	0%	Visco et al. 2017³¹

*not restricted to MCL.

ASCT, autologous stem cell transplantation; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CR, complete response rate; CVP, cyclophosphamide, vincristine, and prednisone; HDA, high-dose cytarabine; HCVAD/MA, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose cytarabine and methotrexate; MCL, mantle cell lymphoma; n, number of patients; NA, not available; OR, overall response rate; OS, overall survival; PFS, progression-free survival; R, rituximab; TRM, treatment-related mortality.